Engage with the leading edge of biopharmaceuticals

Tumor Targeting

BXQ-350 nanovesicles target and identify tumors. In preclinical mouse and rat models, our nanovesicles specifically seek and exclusively localize within tumors, even metastasized and spontaneous tumors.

Bexion’s BXQ-350 targets what appear to be ubiquitous phosphatidylserine (PS) lipids on tumor cells and the blood vessels that feed them, resulting in efficacy being observed across a wide variety of cancer types. Selectivity is achieved by activation based on local pH. Because the key biologic in BXQ-350 is a lysosomal protein, it is inactive at normal physiological pH’s, becoming active only in the acidic microenvironments inherent in solid tumors, including brain tumors.

Spontaneous glioblastoma in a mouse made visible by labeling with BXQ-350-CVM.

Video by: X. Qi, K. LaSance, L. Lemen, Z. Chu (University of Cincinnati), B. Kaur, C-H. Kwon (Ohio State University)

BXQ-350 nanovesicles target and identify tumors.
Left: BXQ-350 with a fluorescent marker, CVM goes directly to pancreatic cancer.
Right: The same tumor, but imaged through luminescence (i.e., tumor manipulated to glow with luciferase).